National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, China.
Front Immunol. 2023 May 5;14:1138203. doi: 10.3389/fimmu.2023.1138203. eCollection 2023.
Glioma, the most prevalent malignant intracranial tumor, poses a significant threat to patients due to its high morbidity and mortality rates, but its prognostic indicators remain inaccurate. Although TRAF-associated NF-kB activator (TANK) interacts and cross-regulates with cytokines and microenvironmental immune cells, it is unclear whether TANK plays a role in the immunologically heterogeneous gliomas.
TANK mRNA expression patterns in public databases were analyzed, and qPCR and IHC were performed in an in-house cohort to confirm the clinical significance of TANK. Then, we systematically evaluated the relationship between TANK expression and immune characteristics in the glioma microenvironment. Additionally, we evaluated the ability of TANK to predict treatment response in glioma. TANK-associated risk scores were developed by LASSO-Cox regression and machine learning, and their prognostic ability was tested.
TANK was specifically overexpressed in glioma and enriched in the malignant phenotype, and its overexpression was related to poor prognosis. The presence of a tumor microenvironment that is immunosuppressive was evident by the negative correlations between TANK expression and immunomodulators, steps in the cancer immunity cycle, and immune checkpoints. Notably, treatment for cancer may be more effective when immunotherapy is combined with anti-TANK therapy. Prognosis could be accurately predicted by the TANK-related risk score.
High expression of TANK is associated with the malignant phenotype of glioma, as it shapes an immunosuppressive tumor microenvironment. Additionally, TANK can be used as a predictive biomarker for responses to various treatments and prognosis.
神经胶质瘤是最常见的颅内恶性肿瘤,由于其高发病率和死亡率,对患者构成了重大威胁,但目前其预后指标仍不够准确。虽然 TRAF 相关 NF-kB 激活剂(TANK)与细胞因子和微环境免疫细胞相互作用和交叉调节,但 TANK 是否在免疫异质性神经胶质瘤中发挥作用尚不清楚。
分析公共数据库中 TANK mRNA 的表达模式,并在内部队列中进行 qPCR 和 IHC 以验证 TANK 的临床意义。然后,我们系统地评估了 TANK 表达与胶质瘤微环境中免疫特征之间的关系。此外,我们评估了 TANK 预测胶质瘤治疗反应的能力。通过 LASSO-Cox 回归和机器学习开发了 TANK 相关风险评分,并对其预后能力进行了测试。
TANK 在神经胶质瘤中特异性过表达,并富集在恶性表型中,其过表达与预后不良相关。TANK 表达与免疫调节剂、癌症免疫周期步骤和免疫检查点呈负相关,表明肿瘤微环境存在免疫抑制。值得注意的是,当免疫疗法与抗 TANK 疗法联合使用时,癌症治疗可能更有效。TANK 相关风险评分可准确预测预后。
TANK 的高表达与神经胶质瘤的恶性表型相关,因为它塑造了一个免疫抑制的肿瘤微环境。此外,TANK 可作为预测各种治疗反应和预后的生物标志物。